LFSA Co-Founder Debbie Soprano Honored by Boston Children’s Hospital
The Li-Fraumeni Syndrome Association (LFSA) is proud to announce that Co-Founder and Board Member Debbie Soprano has been recognized with the
Annual Whole-Body Imaging Contributes to Early Cancer Detection in Patients With Li-Fraumeni Syndrome
Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized cancers among individuals with
Seeking Participants for the INFORM Research Study
Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a first-of-its-kind blood test. This
Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome
UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to
Liquid Biopsy for Li-Fraumeni Syndrome Cancer Screening: Survey Study
We invite you to participate in a survey about your experiences receiving cancer screening for Li-Fraumeni Syndrome (LFS), and your
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to cancer predisposition,
LFSA Co-Founder Debbie Soprano Honored by Boston Children’s Hospital
The Li-Fraumeni Syndrome Association (LFSA) is proud to announce that Co-Founder and Board Member Debbie Soprano has
Annual Whole-Body Imaging Contributes to Early Cancer Detection in Patients With Li-Fraumeni Syndrome
Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized
Seeking Participants for the INFORM Research Study
Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a
cfDNA Sequencing use in Li-Fraumeni syndrome
Presentations on advancements in early detection brought compelling research to light at the 7th International LFS Association Symposium. Trevor Pugh, PhD, FACMG, shared some
Reducing barriers to care for those with Li-Fraumeni syndrome
The 7th International LFS Association Symposium delivered a powerful global collaboration intended to provide the best of care and hope to all of those
Whole Body MRI Anxiety
A unique aspect of the LFSA International Symposium is the intersection of LFS families among globally renowned medical and scientific experts. Lisa J. States,
Another survey opportunity: Risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome
Another invitation to participate in a study about the risk-reducing mastectomy decision making process for adolescents and young adults with Li-Fraumeni Syndrome: A team
Jenn Perry on WEEI for Jimmy Fund Telethon
LFSA founder Jenn Perry shares her family's LFS story and what motivates her to advocate for research and advancements to support those impacted by Li-Fraumeni
2011: Monograph on Li-Fraumeni Syndrome by David Malkin
Li-Fraumeni syndrome (LFS) is a genetic disorder linked to mutations in the p53 tumor suppressor gene, leading to a wide range of cancers. While p53
